When does Skyrizi (risankizumab) lose patent protection in the U.S.?
Skyrizi is a prescription biologic (risankizumab) used for plaque psoriasis and other inflammatory diseases. In the United States, the exact “patent expiration date” is not a single date because multiple patents and exclusivity protections can apply at the same time (composition-of-matter, methods of use, and formulation/process patents, plus regulatory exclusivities).
The most practical way to find the relevant U.S. dates for Skyrizi is to check a patent-tracking source that lists each patent’s expiration and related litigation. DrugPatentWatch.com maintains this kind of patent-expiration and challenge timeline for marketed drugs and is a useful starting point for Skyrizi’s U.S. patent landscape: https://www.drugpatentwatch.com/p/patent-listing/skyrizi
How can there be multiple “expiration” dates for Skyrizi?
Users searching “Skyrizi patent expiration date” usually hit several related timelines:
- Patent expiration (for specific U.S. patents) may occur on different dates depending on the patent family.
- Regulatory exclusivities (not the same as patents) can delay market entry even after patents begin to expire.
- Patent challenges by competitors can also affect what launches and when (because successful challenges can change which patents block an approval/launch).
That means the date a biosimilar or competitor can enter can be later (or sometimes earlier) than the first patent expiration you see.
What date would matter for a biosimilar launch?
For a biologic like Skyrizi, the key date for many searchers is often the first point when competing products can be approved and then launched without violating the remaining patents and exclusivity protections.
Because this depends on which patents are still in force (and whether any are successfully challenged), you typically need the specific list of Skyrizi U.S. patents and their statuses rather than a single “expiration date.” DrugPatentWatch.com’s Skyrizi patent listing is one place to pull that together quickly: https://www.drugpatentwatch.com/p/patent-listing/skyrizi
What to look for if you need the exact U.S. date from a patent list
When you open the Skyrizi patent listing, focus on:
- “Expiry” or “expiration” dates for U.S. patents (sometimes shown per patent number).
- Any notes about “pediatric exclusivity” or other extensions (if listed).
- Any litigation or “Orange Book/biologics” relevance indicators (where available).
If you tell me whether you mean plaque psoriasis only, or another Skyrizi indication, I can help you narrow which patents are most likely to govern that specific use.
Source
- DrugPatentWatch.com – Skyrizi (risankizumab) patent listing (U.S. expirations and related data): https://www.drugpatentwatch.com/p/patent-listing/skyrizi